BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Executive Summary
Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up
You may also be interested in...
Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says
No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says
No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
Senate Follow-On Biologics Bill Still Stuck In Evergreen Forest
Despite moving a bill out of committee last session, the Senate is still wrangling over the issue of whether modifications of existing products should get full exclusivity.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: